Zidesamtinib Offers a Post-TKI Option in ROS1 NSCLC
Zidesamtinib offers a new post-TKI option for ROS1-positive NSCLC, with reported intracranial activity, while accelerated approval leaves clinical benefit, durability, and optimal sequencing uncertain.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.